within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M05B_DrugsAffectingBoneStructureAndMineralization.M05BA06_IbandronicAcid;

model IbandronicAcid_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.006,
    Cl = 1.3333333333333332e-06,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.003,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.009166666666666667,
    Tlag = 600,
    Vdp = 0.002,
    k12 = 1.8055555555555557e-06,
    k21 = 1.8055555555555557e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>IbandronicAcid_1</td></tr><tr><td>ATC code:</td><td>M05BA06_1</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>80</td><td>ml/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ibandronic acid (ibandronate) is a bisphosphonate drug used primarily for the prevention and treatment of osteoporosis in postmenopausal women. It reduces bone resorption by inhibiting osteoclast-mediated bone loss. Ibandronic acid is approved for clinical use in several countries as both oral and intravenous formulations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy postmenopausal women after 50 mg oral dose.</p><h4>References</h4><ol><li><p>Croom, KF, &amp; Scott, LJ (2006). Intravenous ibandronate: in the treatment of osteoporosis. <i>Drugs</i> 66(12) 1593–1603. DOI:<a href=\"https://doi.org/10.2165/00003495-200666120-00005\">10.2165/00003495-200666120-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16956306/\">https://pubmed.ncbi.nlm.nih.gov/16956306</a></p></li><li><p>Chiu, WY, et al., &amp; Reginster, JY (2020). Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women. <i>Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA</i> 31(1) 193–201. DOI:<a href=\"https://doi.org/10.1007/s00198-019-05127-y\">10.1007/s00198-019-05127-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31642977/\">https://pubmed.ncbi.nlm.nih.gov/31642977</a></p></li><li><p>Pillai, G, et al., &amp; Steimer, JL (2006). Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females. <i>International journal of clinical pharmacology and therapeutics</i> 44(12) 655–667. DOI:<a href=\"https://doi.org/10.5414/cpp44655\">10.5414/cpp44655</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17190376/\">https://pubmed.ncbi.nlm.nih.gov/17190376</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M05BA06_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end IbandronicAcid_1;
